Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › DFTX
SILVERARC CAPITAL MANAGEMENT, LLC position in DFTX
DEFINIUM THERAPEUTICS INC · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 345,946 shares of DFTX (DEFINIUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$13.2M, representing 1.68% of its reported portfolio and ranking #17 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed DFTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's DFTX position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in DFTX in Q2 2026 at 400,000 shares (US$18.8M). Across 2 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 345,946 shares valued at US$13.2M — a reduction of -54,054 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 400.00K | $18.82M | New |
| Q3 2026 | 345.95K | $13.17M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DFTX and 13F data
DFTX (DEFINIUM THERAPEUTICS INC) is a Health Care company. 158 other funds we track also report a position in DFTX — the largest reported positions include Avoro Capital Advisors LLC (US$338.2M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$322.0M), Octagon Capital Advisors LP (US$138.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DFTX
- Avoro Capital Advisors LLC 7.19M sh · $338.17M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.85M sh · $322.00M · Q2 2026
- Octagon Capital Advisors LP 2.95M sh · $138.77M · Q2 2026
- Deep Track Capital, LP 2.75M sh · $129.36M · Q2 2026
- Commodore Capital LP 2.00M sh · $94.08M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.50M sh · $70.56M · Q2 2026
- Boxer Capital Management, LLC 998.50K sh · $46.97M · Q2 2026
- AWM Investment Company, Inc. 784.80K sh · $36.92M · Q2 2026
- ArrowMark Colorado Holdings LLC 564.07K sh · $26.53M · Q2 2026
- Catalio Capital Management, LP 562.67K sh · $26.47M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $25.87M · Q2 2026
- GREAT POINT PARTNERS LLC 425.00K sh · $19.99M · Q2 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held DFTX?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed DFTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in DFTX?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 345.95K shares of DFTX (DEFINIUM THERAPEUTICS INC), valued at $13.17M, representing 1.68% of its reported portfolio and ranking #17.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling DFTX?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in DFTX.
Which other funds hold DFTX?
Other major institutional holders of DFTX include Avoro Capital Advisors LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, Octagon Capital Advisors LP, among 158 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.